BEAM peer analysis
Beam Therapeutics (BEAM) against its competitors: price, today's move, 1-year return and market value side by side.
BEAM and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALLO Allogene Therapeutics | $0.83 | 0.96% | -32.12% | $289.27M |
| CLLS Cellectis | $1.33 | -3.62% | -63.56% | $133.97M |
| CRBU Caribou Biosciences | $0.36 | -5.29% | -84.07% | $38.90M |
| CRSP CRISPR Therapeutics | $42.52 | -0.24% | -18.53% | $4.12B |
| DTIL Precision BioSciences | $7.56 | -5.97% | 26.00% | $211.19M |
| EDIT Editas Medicine | $2.10 | -1.87% | -22.22% | $324.11M |
| FATE Fate Therapeutics | $1.26 | -5.97% | 21.15% | $153.18M |
| NTLA Intellia | $9.80 | -7.11% | 3.27% | $1.38B |
| BEAM Beam Therapeutics | $23.07 | -3.99% | 5.49% | $2.39B |
- BEAM's peers: ALLO (Allogene Therapeutics), CLLS (Cellectis), CRBU (Caribou Biosciences), CRSP (CRISPR Therapeutics), DTIL (Precision BioSciences), EDIT (Editas Medicine), FATE (Fate Therapeutics), NTLA (Intellia).
Updated 2026-11-15 15:40 UTC